![Paul Fry](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Paul Fry
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Avacta Life Sciences Ltd.
![]() Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Paul Fry via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AFFYMETRIX, INC. | Medical Specialties | Corporate Officer/Principal | |
SAREUM HOLDINGS PLC | Miscellaneous | Director/Board Member | |
RENEURON GROUP PLC | Pharmaceuticals: Major | Director/Board Member | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Chief Executive Officer | |
Atlantic Healthcare Plc
![]() Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Oxford BioTherapeutics Ltd.
![]() Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
University of Oxford | College/University | Undergraduate Degree | |
University of Cambridge | College/University | Doctorate Degree | |
CABI Publishing
![]() CABI Publishing Publishing: Books/MagazinesConsumer Services CABI Publishing provides publishing services. The company was founded in 1910 and is headquartered in Wallingford, the United Kingdom. | Publishing: Books/Magazines | Chief Executive Officer | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
ReNeuron Ltd.
![]() ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Director/Board Member | |
AVACTA GROUP PLC | Miscellaneous Commercial Services | Director/Board Member Founder Director of Finance/CFO Chairman Director/Board Member | |
PROTALIX BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal | |
European Molecular Biology Organization | Corporate Officer/Principal | ||
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Iksuda Therapeutics Ltd.
![]() Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Biotechnology | Director/Board Member | |
Ossianix, Inc.
![]() Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Generic | Chairman | |
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Genomics England Ltd.
![]() Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Office for Strategic Co-ordination of Health Research | Director/Board Member | ||
Levicept Ltd.
![]() Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chief Executive Officer | |
MedCity Ltd. | Chairman | ||
BliNK Biomedical SAS
![]() BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Biotechnology | Director/Board Member | |
Gammadelta Therapeutics Ltd.
![]() Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Creabilis SA | Chief Executive Officer | ||
F-Star Delta Ltd.
![]() F-Star Delta Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., F-Star Delta Ltd. develops antibody products to improve the treatment of serious diseases. The company is based in Cambridge, UK and was founded in 2016. | Pharmaceuticals: Major | Director/Board Member | |
The Club Cricket Organisation Ltd. | Director/Board Member | ||
F-star Therapeutics Ltd.
![]() F-star Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
Ochre Bio Ltd.
![]() Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman | |
IMMATICS N.V. | Biotechnology | Director/Board Member | |
F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Ossianix Uk Ltd. | Director/Board Member | ||
IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer | |
Spinifex Pty Ltd. | Director/Board Member | ||
Atlantic Pharmaceuticals (Holdings) Ltd. | Director/Board Member | ||
Immunocore Ltd.
![]() Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Chief Executive Officer | |
Liverpool Health Partners Ltd. | Chairman | ||
Tessellate Bio BV
![]() Tessellate Bio BV BiotechnologyHealth Technology Tessellate Bio BV is a Dutch preclinical stage biotechnology company that focuses on discovering and developing precision oncology medicines. The company is based in Naarden, the Netherlands. The company's mission is to turn cancer patients into cancer survivors by targeting unexplored or difficult to drug pathways beyond HRD. The company is also developing companion diagnostics, including a potentially diagnostic to detect ALT positive cancers. Led by an experienced team of drug hunters, Tessellate Bio is building a pipeline of first-in-class medicines based on cutting-edge research. The company was founded by Hilda A. Pickett and the CEO is Andree Blaukat. | Biotechnology | Director/Board Member | |
Sparta Biodiscovery Ltd.
![]() Sparta Biodiscovery Ltd. Medical SpecialtiesHealth Technology SPARTA Biodiscovery Ltd. manufactures instruments for chemical analysis and pharmaceutical research. The company is based in London, UK. The British company was founded by Molly M. Stevens. The CEO is Jelle Penders. | Medical Specialties | Chairman | |
F-star Biotechnology Ltd.
![]() F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Pfizer Holdings International Luxembourg (PHIL) SARL
![]() Pfizer Holdings International Luxembourg (PHIL) SARL Financial ConglomeratesFinance Part of Pfizer Inc., Pfizer Holdings International Luxembourg (PHIL) SARL is an investment holding company. The company is based in Luxembourg, Luxembourg. | Financial Conglomerates | Corporate Officer/Principal |
Statistieken
Internationaal
Verenigd Koninkrijk | 35 |
Verenigde Staten | 5 |
Duitsland | 4 |
Australië | 3 |
Luxemburg | 3 |
Sectoraal
Health Technology | 34 |
Consumer Services | 5 |
Commercial Services | 3 |
Miscellaneous | 2 |
Finance | 2 |
Operationeel
Director/Board Member | 53 |
Chief Executive Officer | 17 |
Chairman | 14 |
Corporate Officer/Principal | 13 |
Independent Dir/Board Member | 8 |
Sterkste connecties
Insiders | |
---|---|
Eliot Forster | 35 |
Tony Gardiner | 22 |
Michael Owen | 20 |
Trevor Nicholls | 19 |
Alastair Smith | 6 |